Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Lancet 2010;375:14471456
Also, if you have had bariatric surgery or are thinking about it, talk to our healthcare professional
Indications and Usage Saxenda (liraglutide) injection 3 mg is indicated in combination with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with body weight greater than 60kg and obesity Adults with overweight in the presence of at least one weight related comorbid condition Limitations of Use Saxenda contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist The safety and effectiveness of Saxenda in pediatric patients with type 2 diabetes have not been established Important Safety Information for Wegovy WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures
If you use insulin, sulfonylureas, blood pressure medications, sedatives, opioids, sleep medications, or other substances, say so clearly
Retatrutide is a formidable molecule
Clinical Trial Context Behind Semaglutide and Tirzepatide The clinical evidence behind semaglutide and tirzepatide is some of the strongest ever produced in obesity medicine
